Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Cesarean Section

December 30, 2021 updated by: Mansoura University

Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Elective Cesarean Section Under Spinal Anesthesia

Preeclampsia is a multifocal syndrome reported in 2-8 % of pregnancies. It is diagnosed in the second half of pregnancy by two separate measurements of systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg in the same arm and proteinuria >300 mg in 24 h urine collection. The risk for serious complications such as pulmonary edema, cerebrovascular accidents, coagulopathy, and hemorrhage is 10 to 30 fold higher among parturients with severe preeclampsia.

Severe preeclampsia is defined by one or more of the following clinical features: severe hypertension (systolic arterial pressure 160 mmHg and/or diastolic arterial pressure 110 mmHg on more than one occasion at least 4 h apart while the patient is on bed rest, renal dysfunction (serum creatinine >1.1mg/dl or doubling of serum creatinine in the absence of another renal disease, platelet count less than <100,000 mm3, acute pulmonary edema, epigastric pain not responding to medical treatment, new-onset cerebral and visual manifestation, hemolysis, elevated liver enzymes and low platelet count syndrome (HELLP syndrome)

Study Overview

Detailed Description

Fluid resuscitation is a key determinant in the management of these parturients. Hypovolemia exacerbates organ failure, whereas volume overload results in pulmonary edema. In this setting, the use of noninvasive hemodynamic monitoring is associated with reduced mortality.

Point-of-care lung ultrasonography is used in many critical care settings as the initial diagnostic imaging study for patients with respiratory symptoms. It is highly sensitive for the diagnosis of pulmonary edema which may occur even without cardiomyopathy or heart failure.

The IVC is a highly compliant vessel that changes its diam¬eter in parallel with changes in blood volume and central venous pressure. Measurement of IVC diameter and col¬lapsibility index using ultrasound through a subcostal approach has been investigated in patients of various settings. The IVC-CI imaging technique may be used to assess the volume status in healthy parturients undergoing routine cesarean delivery as well as in high-risk parturients as preeclampsia.

Cerebral edema is predominantly vasogenic and may be related to the failure of cerebral autoregulation with subsequent hyperperfusion, blood-brain barrier disruption, and endothelial cell dysfunction. Ultrasonographic measurements of the optic nerve sheath diameter (ONSD) correlate with signs of raised ICP.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • DK
      • Mansoura, DK, Egypt, 050
        • Mansoura university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 45 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

The calculated sample size of the study will be 70 parturients at 5% level of significance and 80 % power, using the following formula:

N= (Z1-α/2+Z1-β) ² σ1* σ2 / δ ² *2 Z1-α/2 = 1.96 Z1-β= 0.842 σ = SD (8, 9) δ = Expected difference to be detected before and after delivery (4). α = Level of acceptability of a false positive result (level of significance=0.05).

β = Level of acceptability of a false negative result (0.20).

1- β= power (0.80).The sample size will be increased to 100 parturients to compensate for protocol failures with incomplete data and to increase the power of the study.

Description

Inclusion Criteria:

  • Singleton pregnancy.
  • 32 - 41 weeks gestational age.
  • Preeclampsia: Blood Pressure ≥140/90 mmHg after 20 weeks' gestation and proteinuria ≥300 mg/24 hours or 1+ on urine dipstick
  • Elective cesarean delivery under spinal anesthesia.

Exclusion Criteria:

  • Body mass index (BMI) ≥40 kg/m2.
  • Significant cardiovascular disease
  • Other obstetrical problems
  • Other uteroplacental problems
  • Abruption placenta.
  • Already treated for acute lung pathology prior to enrollment.
  • Contraindications to spinal anesthesia.
  • INR >1.5 or PLT<100,000 /mm3.
  • Women presenting in labor.
  • Previous thoracic surgery.
  • Previous ocular surgery
  • Ocular trauma
  • Glaucoma.
  • Preoperative pulmonary disease:
  • Increased serum creatinine level ≥1.1 mg/dL.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Lung Ultrasound (LUS) Examination
Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Fentanyl 15 μg will be administered in the subarachnoid space
Lower segment cesarean section using the Pfannenstiel incision
Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
1000 ml ringer acetate will be administered over 2 hours.
Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ultrasonographic fluid assessment
Time Frame: Time frame:preoperative(baseline) and 2 hours after spinal anesthesia.
Detection of change in overall number of B lines (ECS) by lung ultrasound
Time frame:preoperative(baseline) and 2 hours after spinal anesthesia.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urine output
Time Frame: For 2 hours after spinal anesthesia
total urine output at 2 hours after spinal anesthesia
For 2 hours after spinal anesthesia
Oliguria
Time Frame: For 2 hours after spinal anesthesia
Incidence of oliguria defined as a total urine output <60 mL/hr
For 2 hours after spinal anesthesia
Ephedrine use
Time Frame: Intraoperative
total ephedrine dose
Intraoperative
Intraoperative bradycardia
Time Frame: Intraoperative
Incidence of bradycardia (Heart rate <50 beats/minute)
Intraoperative
Incidence of nausea and vomiting.
Time Frame: Intraoperative
Incidence of nausea and/or vomiting as reported by the patient
Intraoperative
Difference between overall number of b lines
Time Frame: baseline and 1hour post spinal
difference between overall number of b lines preoperative(baseline) and at 1 hour after spinal anesthesia.
baseline and 1hour post spinal
Inferior Vena Caval Diameters
Time Frame: Baseline, and at 1 and 2 hours post-spinal
Maximum, minimum inferior vena cava diameters and inferior vena cava collapsibility index changes over time.
Baseline, and at 1 and 2 hours post-spinal
Difference between optic nerve sheath diameter
Time Frame: baseline,at 1hour and at 2 hours of spinal anesthesia.
optic nerve sheath diameter changes over time.
baseline,at 1hour and at 2 hours of spinal anesthesia.
Neonatal Apgar score
Time Frame: 5 min after delivery
neonatal Apgar score to assess neonatal wellbeing at 5 min after delivery
5 min after delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Aboelnour E Aboelnour, MD, Professor of Anesthesia and Surgical Intensive care,
  • Study Director: Hanaa A Elbendary, MD, Assistant Professor, MD anesthesia Department, Faculty of Medicine, Mansoura University, Egypt.
  • Principal Investigator: Marwa L Abdo, MD, lecturer of Anesthesia and Surgical Intensive care,

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2020

Primary Completion (Actual)

August 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

April 29, 2020

First Submitted That Met QC Criteria

April 29, 2020

First Posted (Actual)

May 1, 2020

Study Record Updates

Last Update Posted (Actual)

January 3, 2022

Last Update Submitted That Met QC Criteria

December 30, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

The data will be available following publication for life-long.

IPD Sharing Access Criteria

the data will be accessible to the investigators .and the PRS administrators with hiding the identifiers for the patients

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preeclampsia

Clinical Trials on Intrathecal Bupivacaine

3
Subscribe